RedHill Biopharma Ltd.
RDHL Nasdaq
SEC CIK 1553846
Follow RedHill Biopharma Ltd.
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY24 | $8M | −$8.3M |
| FY23 | $6.5M | $23.9M |
| FY22 | $61.8M | −$71.7M |
| FY21 | $85.8M | −$97.7M |
| FY20 | $64.4M | −$76.2M |
| FY19 | $6.3M | −$42.3M |
| FY18 | $8.4M | −$38.8M |
| FY17 | $4M | −$45.5M |
| FY16 | $101K | −$29.4M |
| FY15 | $3K | −$21.1M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY24 | 60.3% | −181.7% | −102.8% |
| FY23 | 47% | 193.4% | 366.2% |
| FY22 | 46.1% | −69.3% | −116% |
| FY21 | 42.4% | −94.6% | −114% |
| FY20 | 42.7% | −99% | −118.4% |
| FY19 | 64.1% | −686.7% | −672.5% |
| FY18 | 66.1% | −470.5% | −464.4% |
| FY17 | 46.9% | −1297% | −1136.6% |
| FY16 | 100% | −30240.6% | −29079.2% |
| FY15 | 100% | −733400% | −703000% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY24 | −$9.4M |
| FY23 | −$35.8M |
| FY22 | −$29.4M |
| FY21 | −$65.2M |
| FY20 | −$49M |
| FY19 | −$40.9M |
| FY18 | −$34.5M |
| FY17 | −$44.9M |
| FY16 | −$28.3M |
| FY15 | −$17.8M |
| FY14 | - |
- RedHill Biopharma Ltd.
- Healthcare median
Show the numbers
| Year | RedHill Biopharma Ltd. | Healthcare median |
|---|---|---|
| FY24 | −102.8% | −47% |
| FY23 | 366.2% | −58% |
| FY22 | −116% | −80.4% |
| FY21 | −114% | −71.9% |
| FY20 | −118.4% | −62.2% |
| FY19 | −672.5% | −46.3% |
| FY18 | −464.4% | −49.6% |
| FY17 | −1136.6% | −45.9% |
| FY16 | −29079.2% | −36% |
| FY15 | −703000% | −38.4% |
| FY14 | - | −35.5% |